Late profound muscle weakness following heart transplantation due to danon disease

Muscle and Nerve

Volumn 47, Issue 1, 2013, Pages 135-137

  Van Der Starre, Pieter ^a   Deuse, Tobias ^a   Pritts, Chad ^a   Brun, Carlos ^a   Vogel, Hannes ^a   Oyer, Philip ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetics; Heart transplantation; Histology; Intensive care; Polyneuromyopathy

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CREATINE KINASE; CYCLOSPORIN; DACLIZUMAB; DOBUTAMINE; LISINOPRIL; LORAZEPAM; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; PREDNISONE; SILDENAFIL; TACROLIMUS;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; COMPLETE HEART BLOCK; CONGESTIVE HEART FAILURE; DANON DISEASE; DNA SEQUENCE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ELECTROMYOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART TRANSPLANTATION; HEMODIALYSIS; HUMAN; IMMUNOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LUNG ARTERY PRESSURE; MALE; MOTOR UNIT POTENTIAL; MUSCLE ACTION POTENTIAL; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOPATHY; NERVE POTENTIAL; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PRIORITY JOURNAL; QRS COMPLEX; SENSORY NERVE; TONIC CLONIC SEIZURE; TRACHEOSTOMY; TRANSTHORACIC ECHOCARDIOGRAPHY; VENTRICULAR NONCOMPACTION;

GLYCOGEN STORAGE DISEASE TYPE IIB; HEART TRANSPLANTATION; HUMANS; MALE; MUSCLE WEAKNESS; YOUNG ADULT;

EID: 84871271032     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23517     Document Type: Article

References (8)

1. Schweickert WD, Hall J. ICU-acquired weakness. Chest 2007; 131: 1541-1549.
2. Griffiths RD, Hall J. Intensive care unit-acquired weakness. Crit Care Med 2010; 38: 779-787.
3. Danon MJ, Oh SJ, DiMauro S, Maniligod JR, Eastwood A, Naidu S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981; 31: 51-57.
4. Maron BJ, Roberts W, Arad M, Haas TS, Spirito P, Wright GB, et al. Clinical outcome and phenotype expression in LAMP2 cardiomyopathy. JAMA 2009; 301: 1253-1259.
5. Ruivo R, Anne C, Sagne C, Gasnier B. Molecular and cellular basis of lysosomal transmembrane protein dysfunction. Biochem Biophys Acta 2009; 1793: 636-649.
6. Zaragoza MV, Arbustini E, Narula J. Noncompaction of the left ventricle: primary cardiomyopathy with an elusive genetic etiology. Curr Opin Pediatr 2007; 19: 619-627.
7. Senzolo M, Ferronato C, Burra P. Neurologic complications after solid organ transplantation. Transpl Int 2009; 22: 269-278.
8. Bui YK, Renella P, Martinez-Agosot JA, Verity A, Madikians A, Alejos JC. Danon disease with typical early-onset cardiomyopathy in a male: focus on a novel LAMP-2 mutation. Pediatr Transplant 2008; 12: 246-250.